Skin signs of gastrointestinal disease

Published on 05/03/2015 by admin

Filed under Dermatology

Last modified 05/03/2015

Print this page

rate 1 star rate 2 star rate 3 star rate 4 star rate 5 star
Your rating: none, Average: 0 (0 votes)

This article have been viewed 2148 times

Chapter 37 Skin signs of gastrointestinal disease

4. List the top ten skin findings suggestive of hepatic and biliary tract disease.

Jaundice Purpura
Pigment changes Loss of body hair
Spider angioma Gynecomastia
Palmar erythema Peripheral edema
Dilated abdominal wall veins Non-palpable gallbladder

Hepatobiliary diseases are associated with alterations of the vasculature, including spider angiomas, palmar erythema, and cutaneous varices. Spider angiomas are classically associated with chronic liver disease, yet may also be seen in pregnancy, oral contraceptive use, and in normal persons, especially children. The vascular spider consists of a coiled central arteriole with smaller vessels radiating outward like the legs of a spider. In chronic liver disease, they are numerous and are found on the face, neck, upper chest, hands, and forearms. “Liver palms” refers to the mottled erythema and increased warmth of the palms (and sometimes the soles of the feet) in chronic liver disease. Palmar erythema also may be seen in pregnancy, lupus erythematous, pulmonary disease, and hyperthyroidism.

Portal venous hypertension due to chronic liver disease leads to the development of collateral circulation, with esophageal varices as an example. In the skin, this is observed as dilation of the abdominal wall veins (Fig. 37-1). Caput medusa refers to the dilated periumbilical veins and has been known for centuries as a marker of advanced liver disease. In men with chronic liver disease, induction of a “hyperestrogen state” (due to a decreased efficacy of estrogen breakdown in the liver) leads to gynecomastia, testicular atrophy; loss of axillary, truncal, and pubic hair; and a female pattern of pubic hair. Purpura, ecchymoses, and gingival bleeding reflect impaired hepatic production of various clotting factors, especially the vitamin K–dependent factors. Peripheral edema and ascites indicate hypoalbuminemia and/or portal venous hypertension.

7. What is pyoderma gangrenosum?

Pyoderma gangrenosum (PG) is a severe ulcerative condition that affects 1 in 100,000 United States citizens per year and, in over 70% of cases, affects the lower legs (Fig. 37-2). It is one of the skin lesions associated with the abdominal pain and bleeding of inflammatory bowel disease. PG originates as a small, tender pustule that breaks down to form a painful, rapidly expanding necrotic ulcer with a cyanotic, raised and undermined edge. Lesions may develop at sites of minor trauma, a phenomenon known as pathergy. The ulcers of PG may become quite large. They frequently heal with a thin, atrophic scar.

Table 37-1. Conditions Associated with GI Bleeding and Skin Lesions

INFLAMMATORY CONDITIONS VASCULAR MALFORMATIONS AND TUMORS
Ulcerative colitis
Crohn’s disease
Henoch-Schönlein purpura
Polyarteritis nodosa
Hereditary hemorrhagic telangiectasia (Osler-Weber-Rendu)
Kaposi’s sarcoma
Blue rubber bleb nevus syndrome
HEREDITARY POLYPOSIS SYNDROMES MISCELLANEOUS
Gardner’s syndrome
Peutz-Jeghers syndrome
Multiple hamartoma syndrome (Cowden’s syndrome)
Ehlers-Danlos syndrome
Pseudoxanthoma elastica

The exact cause of PG is unknown, but immune complex–mediated neutrophilic vascular reactions in the skin have been postulated. After the diagnosis of PG is made, the next step should be to look for an underlying cause. Important conditions to search for include chronic infectious hepatitis, inflammatory bowel disease (ulcerative colitis or Crohn’s disease), rheumatoid arthritis, lupus erythematosus, HIV infection, and leukemia. About 2% of patients with ulcerative colitis have PG, and the course of both illnesses maybe parallel. Some patients may have PG for several years before developing inflammatory bowel disease. In general, firstline treatment is corticosteroids and cyclosporine. Infliximab (TNF-α antibody) is the treatment of choice for PG with underlying inflammatory bowel disease or rheumatoid arthritis.

Brooklyn T, Dunnill G, Probert C: Diagnosis and treatment of pyoderma gangrenosum, BMJ 333(7560):181–184, 2006.